Skip to main content
TipRanks
Go Ultimate75% OFF

Sinopharm Tech Holdings Limited (8156) AI Stock Analysis

0 Followers
HK:8156

Sinopharm Tech Holdings Limited

(HKEX:8156)

Select Model
Rating:39Underperform
Price Target:HKD 0.15â–¼(-5.23% Downside)
Action:downgraded
Date:11/11/26

The score is driven primarily by severely weak financial performance, including negative equity, recurring losses, and generally negative cash flow. Weak technical momentum and the lack of valuation support further reduce the score, although oversold momentum readings and reduced debt provide limited mitigating factors.

Positive Factors
Debt ReductionDebt has declined from prior-year levels, which is a constructive balance-sheet development and could gradually reduce financing pressure if sustained. However, the improvement remains limited because debt is still meaningful relative to assets and the company continues to have negative equity.
Negative Factors
Sharp Revenue ContractionThe steep 2026 revenue decline highlights significant instability in the company’s commercial performance and weakens earnings visibility. A contraction of this magnitude can reduce operating leverage, limit reinvestment capacity, and make a sustained recovery more difficult over the next several quarters.

Sinopharm Tech Holdings Limited (8156) vs. iShares MSCI Hong Kong ETF (EWH)

-80%-60%-40%-20%0%20%HK:8156-55.00%EWH+8.17%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 96.96M
Dividend Yield
―
Average Volume (3M)
49.66K
Price to Earnings (P/E)
-5.6
Beta (1Y)
0.32
Revenue Growth
-25.58%
EPS Growth
-12.50%
Country
Hong Kong
Employees
31
Sector
Technology
Sector Strength
61
Industry
Software - Application

Sinopharm Tech Holdings Limited Business Overview & Revenue Model

Company Description

Sinopharm Tech Holdings Limited functions as an investment holding enterprise, with its primary focus on lottery operations across mainland China and Hong Kong. The company diversifies its activities into several key areas: it supplies both hardware...

Sinopharm Tech Holdings Limited Financial Statement Overview

Summary

Financial performance is severely weak: revenue and profitability are volatile and predominantly loss-making, shareholders’ equity is persistently negative, and operating and free cash flow are usually negative. Reduced debt and lower recent cash burn provide limited support, but the provided income statement, balance sheet, and cash flow scores are all below the permitted minimum.

Income Statement

27Negative

Balance Sheet

18Very Negative

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue78.53M45.58M61.25M41.28M42.84M40.98M
Gross Profit13.60M6.42M13.52M5.02M5.47M5.10M
EBITDA2.75M-6.94M6.11M4.98M-1.01M-75.17M
Net Income-1.77M-9.14M-867.00K-19.70M-10.63M-88.00M
Balance Sheet
Total Assets22.44M22.44M51.74M44.49M33.48M76.89M
Cash, Cash Equivalents and Short-Term Investments5.62M5.62M6.95M2.64M1.78M2.99M
Total Debt30.73M30.73M46.73M73.26M53.00M45.93M
Total Liabilities71.32M71.32M88.43M250.09M213.24M250.28M
Stockholders Equity-46.40M-46.40M-36.87M-199.48M-172.73M-166.78M
Cash Flow
Free Cash Flow-3.48M-4.02M-7.21M-12.58M4.73M-36.88M
Operating Cash Flow-5.93M-4.02M-7.21M-9.25M4.73M-36.76M
Investing Cash Flow-8,0002,000-9,000-4.86M2,000-85.00K
Financing Cash Flow12.01M3.07M11.50M14.98M-4.52M32.24M

Sinopharm Tech Holdings Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.15

Price Trends

50DMA0.19Negative
100DMA0.18Negative
200DMA0.23Negative

Market Momentum

MACD-0.01Positive
RSI40.37Neutral
STOCH25.39Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8156, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.19, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 40.37 is Neutral, neither overbought nor oversold. The STOCH value of 25.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8156.

Sinopharm Tech Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

HK:8156 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:9885HK:988569NeutralHKD 2.27B10.477.63%3.76%16.99%126.15%
HK:2571HK:257168NeutralHKD 2.03B323.110.76%―-2.29%-91.48%
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%
HK:2576HK:257655NeutralHKD 2.55B-33.21-5.91%―――
HK:8148HK:814850NeutralHKD 1.60B85.3621.60%―151.97%―
HK:8156HK:815639UnderperformHKD 96.96M-5.6220.88%―-25.58%-12.50%

* Technology Sector Average

Performance Comparison

-50%0%50%100%HK:8156HK:8148HK:9885HK:2576HK:2571HK:6687Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:8156 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:8156Sinopharm Tech Holdings Limited0.15-0.19-55.00%
HK:8148Aurum Pacific (China) Group Ltd.3.501.5983.25%
HK:9885YSB Inc.3.33-4.16-55.60%
HK:2576Zhejiang Taimei Medical Technology Co Ltd Class H4.510.255.74%
HK:2571Beijing Saimo Technology Co. Ltd. Class H15.202.4218.94%
HK:6687JST Group Corporation Limited11.94-17.64-59.63%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026